- Home
- RMCO vs KZR Comparison
RMCO vs KZR Comparison
Compare RMCO & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | KZR |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 45.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMCO | KZR |
|---|---|---|
| Price | $4.15 | $6.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 43.6K | 35.8K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,798,352.00 | N/A |
| Revenue This Year | $531.90 | N/A |
| Revenue Next Year | $200.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 445.90 | N/A |
| 52 Week Low | $0.91 | $3.53 |
| 52 Week High | $5.00 | $6.65 |
Technical Indicators
Market Signals| Indicator | RMCO | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 42.22 |
| Support Level | $3.90 | $6.10 |
| Resistance Level | $4.61 | $6.23 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 51.15 | 25.93 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.